Inari Medical, Inc.
NARIDelisted Feb 19, 2025- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001531048
Inari Medical, Inc. was delisted on Feb 19, 2025; its insiders filed their last Form 4 on Feb 19, 2025; 260 institutions reported holding it in 13F filings for Q4 2024, worth $2.80B in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 260
- Q4 2024, +20 vs. previous quarter
- 13F value
- $2.80B
- Reported value at the end of Q4 2024
- Superinvestors holding
- 0
- At the end of Q4 2024
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2023
- $493.6M
- +28.7% year over year
- Net income, FY2023
- -$1.64M
- No comparable prior period
- Free cash flow, FY2023
- $31.2M
- No comparable prior period
- Revenue, Q3 FY2024
- $153.4M
- +21.4% year over year
Revenue flow, FY2023
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2023: $1.64M (0.3% of revenue).
Superinvestors holding NARI, Q4 2024
Go to the superinvestors tabNo superinvestor reported holding NARI at the end of Q4 2024.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Inari Medical, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Hoffman WilliamDirector | SSale | −200.0K | $60.47 | −$12.1M | −45.6%239.0K after | 2 lots10b5-1 |
| Dec 20, 2024 (view filing) | Dec 20 | Same day | Hykes AndrewPresident and CEO | SSale | −3.00K | $55.29 | −$165.9K | −0.7%439.3K after | 2 lots10b5-1 |
| Dec 18, 2024 (view filing) | Dec 16 | 2 days | Hoffman WilliamDirector | SSale | −60.0K | $55.66 | −$3.34M | −12.0%441.2K after | 8 lots10b5-1 |
| Dec 12, 2024 (view filing) | Dec 10 | 2 days | Tu ThomasChief Medical Officer | SSale | −4.00K | $55.00 | −$220.0K | −1.3%304.0K after | 10b5-1 |
| Nov 22, 2024 (view filing) | Nov 20 | 2 days | Hykes AndrewPresident and CEO | SSale | −3.00K | $50.83 | −$152.5K | −0.7%442.3K after | 10b5-1 |
| Nov 20, 2024 (view filing) | Nov 18 | 2 days | Hoffman WilliamDirector | SSale | −60.0K | $51.16 | −$3.07M | −10.7%501.2K after | 5 lots10b5-1 |
| Oct 31, 2024 (view filing) | Oct 29 | 2 days | Hykes AndrewPresident and CEO | SSale | −3.00K | $50.00 | −$150.0K | −0.7%445.3K after | 10b5-1 |
| Oct 31, 2024 (view filing) | Oct 29 | 2 days | Hoffman WilliamDirector | SSale | −40.0K | $50.05 | −$2.00M | −6.7%561.2K after | 2 lots10b5-1 |
| Oct 18, 2024 (view filing) | Oct 16 | 2 days | Hoffman WilliamDirector | SSale | −40.0K | $45.02 | −$1.80M | −6.2%601.2K after | 2 lots10b5-1 |
| Sep 18, 2024 (view filing) | Sep 16 | 2 days | Hoffman WilliamDirector | SSale | −40.0K | $45.83 | −$1.83M | −5.9%643.3K after | 2 lots10b5-1 |
Top 10 13F holders, Q4 2024
See all 260 holdersThe largest institutional positions in Inari Medical, Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,389,788 | $428.3M | 0.01% | +64,682+0.8% | Added |
| Vanguard Group Inc | 5,628,875 | $287.4M | 0.01% | +30,702+0.5% | Added |
| HCC Manager LLC | 2,914,246 | $148.8M | 93.92% | 00.0% | Unchanged |
| Morgan Stanley | 2,150,771 | $109.8M | 0.01% | +989,513+85.2% | Added |
| State Street Corp | 2,083,195 | $106.3M | 0.00% | +47,593+2.3% | Added |
| Brown Advisory Inc | 1,811,136 | $92.5M | 0.12% | −14,626−0.8% | Reduced |
| Jennison Associates LLC | 1,763,258 | $90.0M | 0.05% | +186,617+11.8% | Added |
| Armistice Capital, LLC | 1,565,577 | $79.9M | 1.86% | −256,423−14.1% | Reduced |
| Mackenzie Financial Corp | 1,363,697 | $69.6M | 0.09% | +509,868+59.7% | Added |
| Bamco Inc | 1,312,528 | $67.0M | 0.17% | +306,399+30.5% | Added |